# Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein

> **NCT02364479** · PHASE4 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 150 (actual)

## Conditions studied

- Spondyloarthritis

## Interventions

- **DRUG:** 50mg Yisaipu
- **DRUG:** 25mg etanercept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02364479
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-10
- **Primary completion:** 2016-07-28
- **Final completion:** 2016-08-28
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2019-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02364479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02364479, "Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02364479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*